• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Novo Nordisk A/S Common Stock (NY:NVO)

    41.59 +0.57 (+1.39%)
    Streaming Delayed Price Updated: 1:23 PM EDT, Jun 9, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 9,017,755
    Open 41.08
    Bid (Size) 41.58 (300)
    Ask (Size) 41.59 (1,600)
    Prev. Close 41.02
    Today's Range 41.08 - 41.91
    52wk Range 35.12 - 81.44
    Shares Outstanding N/A
    Dividend Yield 6.13%
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    80% of Wegovy Pill Users Never Took a Weight Loss Drug Before. Does This Number Change the Entire Novo Nordisk Bear Case? ↗
    Novo Nordisk could maintain this latest early-mover advantage longer than you think. 
    Via The Motley Fool
    News headline image
    Novo's Wegovy Pill Isn't Just Beating Expectations -- It's Obliterating Them. Is the Beaten-Down Stock a Buy Now? ↗
    Investors appear to have left Novo Nordisk behind as they focus on Eli Lilly; that could be a mistake. 
    Via The Motley Fool
    Topics Intellectual Property

    Performance

    YTD
    -20.6%
    -20.6%
    1 Month
    -10.4%
    -10.4%
    3 Month
    +4.6%
    +4.6%
    6 Month
    -11.1%
    -11.1%
    1 Year
    -44.9%
    -44.9%

    More News

    Read More
    News headline image
    CVS Health Just Announced Fantastic News to Eli Lilly Stock Investors ↗
    Via The Motley Fool
    News headline image
    Eli Lilly Sees More Dealmaking Ahead as Management Looks To Leverage Its GLP-1 Success ↗
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    Forget Zepbound: Eli Lilly's Next Billion-Dollar Weight-Loss Drug May Be Even Better ↗
    Via The Motley Fool
    News headline image
    Here's What I Think Is Really Going on With Novo Nordisk Stock ↗
    Via The Motley Fool
    News headline image
    Bull vs. Bear: The Quick Take on Viking Therapeutics Stock ↗
    Via The Motley Fool
    News headline image
    Eli Lilly Wins Back CVS Health, Reverting Novo's Advantage ↗
    Via MarketBeat
    News headline image
    Viking Therapeutics' Q3 Catalyst That Could Turn Eli Lilly's and Novo Nordisk's Daily Weight Loss Pill Strategy Upside Down ↗
    Via The Motley Fool
    News headline image
    Lexicon (LXRX) Q1 2026 Earnings Transcript ↗
    Via The Motley Fool
    News headline image
    Is Eli Lilly Starting an Nvidia-Style Run? ↗
    Via The Motley Fool
    Topics Artificial Intelligence
    News headline image
    5 Best Growth Stocks for the Next 10 Years ↗
    Via MarketBeat
    Topics Artificial Intelligence Economy
    News headline image
    Lilly's New Drug Just Delivered the Largest Weight Loss Ever Seen in a Clinical Trial -- Here's What It Means for Investors ↗
    Via The Motley Fool
    News headline image
    The Smartest Growth Stocks to Buy With $2,000 Right Now ↗
    Via The Motley Fool
    Topics Artificial Intelligence
    News headline image
    Stock Split Watch: Is Eli Lilly Next? ↗
    Via The Motley Fool
    News headline image
    Contrarian Opinion: Novo Nordisk Is A Better Buy Than Eli Lilly Right Now ↗
    Via The Motley Fool
    News headline image
    Hims & Hers Eyes Global Growth: Will $1.15B Eucalyptus Deal Fuel Its Recovery or Dilute Shareholders? ↗
    Via MarketBeat
    Topics Earnings
    News headline image
    Novo Nordisk Is Beating Eli Lilly in the Obesity Pill Market. Should Lilly Investors Be Worried? ↗
    Via The Motley Fool
    News headline image
    President Trump Loaded Up on Eli Lilly in Q1. Should You Buy the Obesity Drug Stock Too? ↗
    Via The Motley Fool
    Topics Government
    News headline image
    Prediction: These 2 Obesity Drug Stocks Could Double in 2026 ↗
    Via The Motley Fool
    News headline image
    Don't Buy Viking Therapeutics Stock Until You Read This ↗
    Via The Motley Fool
    News headline image
    Eli Lilly Just Got a Huge Vote of Confidence From Morgan Stanley -- and It's All About Mounjaro ↗
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    Eli Lilly Just Made a Game-Changing Move in the Billion-Dollar Weight Loss Drug Space. Here's What You Need to Know. ↗
    Via The Motley Fool
    News headline image
    The Silver Lining of Last Week's Hims & Hers Earnings Miss ↗
    Via MarketBeat
    Topics Earnings
    News headline image
    Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
    Via FinancialNewsMedia
    Topics Government

    Frequently Asked Questions

    Is Novo Nordisk A/S Common Stock publicly traded?
    Yes, Novo Nordisk A/S Common Stock is publicly traded.
    What exchange does Novo Nordisk A/S Common Stock trade on?
    Novo Nordisk A/S Common Stock trades on the New York Stock Exchange
    What is the ticker symbol for Novo Nordisk A/S Common Stock?
    The ticker symbol for Novo Nordisk A/S Common Stock is NVO on the New York Stock Exchange
    What is the current price of Novo Nordisk A/S Common Stock?
    The current price of Novo Nordisk A/S Common Stock is 41.59
    When was Novo Nordisk A/S Common Stock last traded?
    The last trade of Novo Nordisk A/S Common Stock was at 06/09/26 01:23 PM ET
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.